India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Quack cardiac surgeries, World Health Day policies, Trump's healthcare decisions, anti-obesity drug coverage, and more health ...